JMP Securities Maintains Market Outperform on CRISPR Therapeutics, Raises Price Target to $80
Portfolio Pulse from Benzinga Newsdesk
JMP Securities analyst Silvan Tuerkcan has maintained a Market Outperform rating on CRISPR Therapeutics (NASDAQ:CRSP) and increased the price target from $74 to $80.
December 11, 2023 | 11:29 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
CRISPR Therapeutics' stock rating was reaffirmed as Market Outperform by JMP Securities, with a raised price target from $74 to $80, indicating a positive outlook.
The reaffirmation of the Market Outperform rating and the increase in price target by JMP Securities are strong indicators of confidence in CRISPR Therapeutics' future performance. This typically has a positive effect on investor sentiment and can lead to a short-term increase in stock price.
CONFIDENCE 90
IMPORTANCE 85
RELEVANCE 100